E-Mail Alert

Add your e-mail address to receive forthcoming issues of this journal:

Journal Browser

Journal Browser

Special Issue "Targeted Therapies and Immuno-Oncology in Melanoma"

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: 30 September 2019

Special Issue Editor

Guest Editor
Dr. Lisa M. Ebert

Centre for Cancer Biology, SA Pathology and University of South Australia, North Tce, Adelaide SA 5001, Australia
Website | E-Mail
Interests: cancer immunotherapy; T cell biology; checkpoint inhibitors; CAR-T cell therapy; melanoma; glioblastoma

Special Issue Information

Dear Colleagues,

We are in the midst of a revolution in the treatment of melanoma. Less than a decade ago, patients with metastatic melanoma had no effective treatment options and prognosis was extremely poor, with melanoma being largely resistant to chemotherapy and radiotherapy. Now, newly developed immunotherapies and targeted therapies are changing this treatment landscape in dramatic ways.

Small molecule inhibitors targeting components of the MAPK signaling pathway (including inhibitors of BRAF and MEK) can induce rapid and dramatic tumor shrinkage. However, these benefits are usually not sustained long term. Identifying mechanisms of resistance and discovering approaches to overcome them has therefore become a key research question. Also of great value would be the identification of treatment strategies that prevent the development of resistance in the first place.

In contrast to targeted therapies, checkpoint blockade immunotherapy (for example, anti-PD1 and anti-CTLA-4) can induce long-lasting tumor regression. However, these deep responses are relatively rare, and the same treatment produces little or no benefit for other patients. The great challenge therefore remains to increase response rates so that all melanoma patients can benefit from this potentially curative treatment. This goal would be significantly advanced by a better understanding of the biology underpinning effective anti-cancer immune responses, and the identification of new therapeutic targets and combination strategies. And until these therapies become effective for all patients, the development of accurate methods to predict who is going to respond will support precision medicine approaches that avoid unnecessary toxicities and  target these expensive therapies to patients who will actually benefit.

This Special Issue welcomes submissions of original clinical research articles, case reports and high-quality reviews that address these and related questions, as well as articles on other novel approaches to melanoma therapy.

Dr. Lisa M. Ebert
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • melanoma
  • targeted therapy
  • immunotherapy
  • checkpoint blockade
  • precision medicine
  • tumor immunology

Published Papers (1 paper)

View options order results:
result details:
Displaying articles 1-1
Export citation of selected articles as:

Review

Open AccessReview
The Clinical Trial Landscape for Melanoma Therapies
J. Clin. Med. 2019, 8(3), 368; https://doi.org/10.3390/jcm8030368
Received: 28 January 2019 / Revised: 7 March 2019 / Accepted: 12 March 2019 / Published: 15 March 2019
Cited by 1 | PDF Full-text (2109 KB) | HTML Full-text | XML Full-text
Abstract
(1) Despite many years of research, melanoma still remains a big challenge for modern medicine. The purpose of this article is to review publicly available clinical trials to find trends regarding the number of trials, their location, and interventions including the most frequently [...] Read more.
(1) Despite many years of research, melanoma still remains a big challenge for modern medicine. The purpose of this article is to review publicly available clinical trials to find trends regarding the number of trials, their location, and interventions including the most frequently studied drugs and their combinations. (2) We surveyed clinical trials registered in the International Clinical Trials Registry Platform (ICTRP), one of the largest databases on clinical trials. The search was performed on 30 November 2018 using the term “melanoma”. Data have been supplemented with the information obtained from publicly available data repositories including PubMed, World Health Organization, National Cancer Institute, Centers for Disease Control and Prevention, European Cancer Information System, and many others to bring the historical context of this study. (3) Among the total of 2563 clinical trials included in the analysis, most have been registered in the USA (1487), which is 58% of the total. The most commonly studied drug in clinical trials was ipilimumab, described as applied intervention in 251 trials. (4) An increase in the number of melanoma clinical trials using immunomodulating monoclonal antibody therapies, small molecule-targeted therapies (inhibitors of BRAF, MEK, CDK4/6), and combination therapies is recognized. This illustrates the tendency towards precision medicine. Full article
(This article belongs to the Special Issue Targeted Therapies and Immuno-Oncology in Melanoma)
Figures

Figure 1

J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top